John Hamer is a Managing Partner at DCVC Bio where he invests in Seed, Early-stage, Series A and Series B startups across Life Sciences and Deep Tech sectors including Biotechnology, AgTech, Health, Energy, Materials, Chemicals, Medicine, Synthetic Biology, Drug Discovery, Genetics and Artificial Intelligence. He is operating a $400M fund raised in September 2024 and invests in companies in the United States (including California and the San Francisco Bay Area), as well as Europe, Asia and the Middle East. He serves on the boards of CIAT (Board of Trustee, 2012–2018) and Chromatin, Inc. (Chairperson, 2008–2012), and has invested in companies like Pivot Bio, Ginkgo Bioworks, Freenome, Recursion Pharmaceuticals and Chroma Medicine. Before DCVC Bio, he held roles including Monsanto Growth Ventures at Monsanto; Managing Director at Burrill & Company; CEO at Arete Therapeutics; CSO/CEO/VP Business Development at Paradigm Genetics (Icoria); Professor of Biological Sciences at Purdue University; and Editor-in-Chief of Fungal Genetics and Biology at Academic Press. John earned a Ph.D. in Microbiology from the University of California, Davis, and an M.Sc. in Biological Sciences and B.Sc. in Biology from the University of Windsor. He lives in San Francisco, California, United States.
John Hamer, Managing Partner @ DCVC Bio. Profile with intro opportunities and ranking information.
Not Yet Mapped
We've created a profile for John Hamer from . Our ranking analysis and additional data will be available once our research is complete.
Rankings and detailed information coming soon
Network Strength
No ranking data available yet.
How to get an intro to John
Map your path to John instantly
Connect your network and Draftboard will automatically find and score the strongest paths to John
That's it. Draftboard does the rest.
Rankings based on connection strength analysis - we ONLY show aggregate data, never specific connection data.